Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,411 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Running Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Tebipenem (SPR994) Crushed Tablet

NCT05296382
View directory record Official record
Conditions
Relative Bioavailability
Interventions
Tebipenem tablet form, Tube feeds
Drug · Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

NCT03351478
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Empagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Sheffield, Alabama • Hawaiian Gardens, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 17, 2026, 8:27 PM EDT
Completed No phase listed Observational

Digital Tools for Assessment of Motor Functions and Falls in ALS

NCT05271435
View directory record Official record
Conditions
ALS, PLS, PMA
Interventions
PAMSys Activity Monitoring System, Motor, Speech, and Handwriting Assessment
Device · Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 8:27 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

NCT05556798
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab Mafodotin, Nirogacestat, Pomalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Results available

A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers

NCT01553084
View directory record Official record
Conditions
Smoking Cessation, Smoking, Nicotine Dependence
Interventions
Varenicline, Nicotine lozenge, Nicotine Patch
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Not applicable Interventional Results available

USS Virginia Closed-Loop for Overnight Control in Type 1 Diabetes

NCT02131766
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
DiAs, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 17, 2026, 8:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prediction of Visual Feedback Effects on Speech Motor Adaptation in Healthy Adults

NCT07530900
View directory record Official record
Conditions
Healthy Volunteers, Speech
Interventions
Altered Auditory Feedback (AAF), Visual-Acoustic Biofeedback
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eyes-Closed Interoceptive Aerobic Exercise Compared With Matched Eyes-Open Treadmill Exercise in Healthy Adults

NCT07625371
View directory record Official record
Conditions
Exercise, Physical Activity, Healthy Adult, Interoception, Affect and Exertion During and Post-exercise
Interventions
Eyes-Closed Interoceptive Aerobic Exercise, Matched Eyes-Open Treadmill Exercise
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Not applicable Interventional

The CARE (Collaborative Adolescent Running Experience) Project

NCT05837351
View directory record Official record
Conditions
Depression, Anxiety, Major Depressive Disorder, Bipolar Disorder
Interventions
Exercise -Running
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Carbohydrates and Running Performance

NCT06742398
View directory record Official record
Conditions
Nutrition, Healthy
Interventions
Carbohydrate Dissolvable Strip, Carbohydrate Mouth Rinse, Water Mouth Rinse
Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure

NCT00303498
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
Sitexsentin sodium, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

NCT04046939
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
36
States / cities
Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Not applicable Interventional

Continuous Adductor Canal Block (CACB) vs. Combined Spinal Epidural (CSE) in Total Knee Arthroplasty

NCT02415465
View directory record Official record
Conditions
Arthroplasty
Interventions
Continuous Adductor Canal Block, General, Epidural, Spinal
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 17, 2026, 8:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Enhancing Attention in Elderly Using a Brain-Computer-Interface

NCT07441122
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
transcranial electrical stimulation, Mindfulness Meditation
Device · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Austin, Texas • Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

NCT03332771
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
115
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 101 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 17, 2026, 8:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252
View directory record Official record
Conditions
Extensive Stage-small Cell Lung Cancer
Interventions
Ifinatamab deruxtecan, Atezolizumab, Carboplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

NCT03475004
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Pembrolizumab, Bevacizumab, Binimetinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

NCT02412111
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Tezacaftor/Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 17, 2026, 8:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Army Training at High Intensity Study

NCT02407093
View directory record Official record
Conditions
Obesity
Interventions
High-Intensity Functional Training, Army Physical Readiness Training
Behavioral
Lead sponsor
Kansas State University
Other
Eligibility
18 Years to 64 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Leavenworth, Kansas • Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 17, 2026, 8:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Graded Exercise Hypoxia Testing

NCT06901284
View directory record Official record
Conditions
Hypoxia
Interventions
Graded Exercise Test, Graded Hypoxia Exercise Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 8:27 PM EDT
Recruiting Not applicable Interventional

Continuous Glucose Monitoring (CGM) in an Underserved Population

NCT07135531
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Type 2
Interventions
Continuous Glucose Monitoring (CGM)
Device
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 8:27 PM EDT
Recruiting Phase 2 Interventional

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

NCT05208307
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Dexamethasone, Pomalidomide
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 17, 2026, 8:27 PM EDT